Trial
NCT04389840
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jazz Pharmaceuticals
Collaborators
—
Condition
Coronavirus Disease 2019 (COVID-19)
Intervention
Dociparstat sodium
Why stopped
Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-30